Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Assessment of kidney function: clinical indications for measured GFR

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Increased incidence and improved prognosis of glomerulonephritis: a national 30-year study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fatal case of hospital-acquired hypernatraemia in a neonate: lessons learned from a tragic error

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Musculoskeletal pain reported by mobile patients with chronic kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Emanuel Zitt
  • Denis Fouque
  • Stefan H Jacobson
  • Fabio Malberti
  • Miroslav Ryba
  • Pablo Ureña
  • Marianne Rix
  • Bastian Dehmel
  • Nick Manamley
  • Marc Vervloet
Vis graf over relationer
The calcimimetic cinacalcet lowers parathyroid hormone (PTH), calcium (Ca) and phosphorus (P) in dialysis patients with secondary hyperparathyroidism (SHPT). We explored serum P changes in dialysis patients treated with cinacalcet, while controlling for vitamin D sterol and phosphate binder (PB) changes, based on data from the pan-European observational study ECHO.
OriginalsprogEngelsk
TidsskriftClinical kidney journal
Vol/bind6
Udgave nummer3
Sider (fra-til)287-294
Antal sider8
ISSN2048-8505
DOI
StatusUdgivet - jun. 2013

ID: 42335981